Description: Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic tests for clinical diagnostics in the area of human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, an early-stage molecular lateral-flow test; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Home Page: mainzbiomed.com
MYNZ Technical Analysis
Robert Koch Strasse 50
Mainz,
55129
Germany
Phone:
49 6131 554 2860
Officers
| Name | Title |
|---|---|
| Mr. Guido Baechler | CEO & Director |
| Mr. William J. Caragol | Chief Financial Officer |
| Mr. Philipp Freese | Chief Operating Officer |
| Dr. Moritz Eidens Ph.D. | Chief Science Officer & Director |
| Mr. Darin S. Leigh | Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.9532 |
| Price-to-Sales TTM: | 276.3724 |
| IPO Date: | 2021-11-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |